These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 12886864)
1. Prophylactic surgery in hereditary breast/ovarian cancer syndrome. Levine DA; Gemignani ML Oncology (Williston Park); 2003 Jul; 17(7):932-41; discussion 946-8, 950-2. PubMed ID: 12886864 [TBL] [Abstract][Full Text] [Related]
2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
3. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Roukos DH; Briasoulis E Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808 [TBL] [Abstract][Full Text] [Related]
4. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443 [TBL] [Abstract][Full Text] [Related]
5. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL; N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993 [TBL] [Abstract][Full Text] [Related]
6. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
7. Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation. Metcalfe KA; Kim-Sing C; Ghadirian P; Sun P; Narod SA Clin Genet; 2014 Jan; 85(1):21-30. PubMed ID: 23859469 [TBL] [Abstract][Full Text] [Related]
8. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. Schrag D; Kuntz KM; Garber JE; Weeks JC N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160 [TBL] [Abstract][Full Text] [Related]
9. Hereditary breast-ovarian cancer: clinical findings and medical management. Marshall M; Solomon S Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820 [TBL] [Abstract][Full Text] [Related]
10. [Prophylactic surgery in common hereditary cancer syndromes]. Noguès C; Mouret-Fourme E Bull Acad Natl Med; 2012 Oct; 196(7):1237-45. PubMed ID: 23815011 [TBL] [Abstract][Full Text] [Related]
11. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241 [TBL] [Abstract][Full Text] [Related]
12. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733 [TBL] [Abstract][Full Text] [Related]
13. [Hereditary breast cancer: treatment and prevention]. Ejlertsen B; Gerdes AM Ugeskr Laeger; 2007 Sep; 169(36):2972-5. PubMed ID: 17953871 [TBL] [Abstract][Full Text] [Related]
15. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. van Roosmalen MS; Verhoef LC; Stalmeier PF; Hoogerbrugge N; van Daal WA J Clin Oncol; 2002 Apr; 20(8):2092-100. PubMed ID: 11956270 [TBL] [Abstract][Full Text] [Related]
16. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. Schrag D; Kuntz KM; Garber JE; Weeks JC JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701 [TBL] [Abstract][Full Text] [Related]
17. Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines. Julian-Reynier C; Eisinger F; Moatti JP; Sobol H Eur J Hum Genet; 2000 Mar; 8(3):204-8. PubMed ID: 10780786 [TBL] [Abstract][Full Text] [Related]
18. Hereditary ovarian cancer--assessing risk and prevention strategies. Pavelka JC; Li AJ; Karlan BY Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862 [TBL] [Abstract][Full Text] [Related]
19. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy. Dowdy SC; Stefanek M; Hartmann LC Am J Obstet Gynecol; 2004 Oct; 191(4):1113-23. PubMed ID: 15507929 [TBL] [Abstract][Full Text] [Related]
20. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA; J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]